ADHD combo drug trial halted after just 2 teens enrolled

NCT ID NCT06673368

Terminated Symptom relief Sponsor: Neurocentria, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 25, 2026 · Last updated May 24, 2026 · Updated 23 times

Summary

This study tested whether adding NRCT-101SR to the existing ADHD drug NRCT-202XR could better control symptoms in teenagers aged 13-17. Only 2 participants were enrolled before the trial was stopped early. The goal was to reduce side effects and improve daily functioning, but no conclusions can be drawn due to the small size.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Accel Research Site-Maitland Clinical Research Unit

Maitland, Florida, 32751, United States
Boston Clinical Trials LLC

Boston, Massachusetts, 02131, United States
CenExel iRS - iResearch Savannah

Savannah, Georgia, 31405, United States
Center For Psychiatry and Behavioral Medicine

Las Vegas, Nevada, 89128, United States
iResearch Atlanta

Decatur, Georgia, 30030, United States

Conditions

Explore the condition pages connected to this study.

ADHD